Improvement of Quality of Life by Means of Antitachy Pacing: From PainFREE to the ADVANCE-D Trial
| Autor: | Massimo Santini, Maurizio Lunati, Johann Mermi, Xavier Navarro, Micaela Passardi, Pascal Defaye, Arcadi García-Alberola, Riccardo Cappato, Angel Arenal, José L. Merino |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Ventricular Tachyarrhythmias medicine.medical_treatment Ventricular tachycardia law.invention Randomized controlled trial Quality of life law Internal medicine medicine Clinical endpoint Humans Randomized Controlled Trials as Topic business.industry Cardiac Pacing Artificial General Medicine Implantable cardioverter-defibrillator medicine.disease Treatment Outcome Shock (circulatory) Quality of Life Tachycardia Ventricular Cardiology Antitachycardia Pacing Female medicine.symptom Cardiology and Cardiovascular Medicine business |
| Zdroj: | Pacing and Clinical Electrophysiology. 29:S35-S39 |
| ISSN: | 1540-8159 0147-8389 |
| DOI: | 10.1111/j.1540-8159.2006.00488.x |
| Popis: | Background: Implantable cardioverter-defibrillators (ICD) can terminate ventricular tachyarrhythmias with shocks (painful) or antitachycardia pacing (painless). According to the results of the Pacing Fast VT Reduces Shock ThErapies Trials, antitachycardia pacing (ATP) can avoid painful shocks and also increase device longevity. The purpose of the ADVANCE-D (Atp DeliVery for PAiNless ICD ThErapy) study is to determine the most appropriate ventricular tachycardia (VT) therapy, so as to optimize painless therapy for life-threatening arrhythmias. Methods and Results: The ADVANCE-D is a prospective, multicenter, parallel, two-arm randomized study designed to evaluate the efficacy of two different sequences of ATP therapies (burst 15 pulses, 88%, vs burst 8 pulses, 88%), during an episode of spontaneous arrhythmia classified as fast VT (FVT) in patients with a Class I or IIA indication for ICD implantation (single and dual chamber devices). The primary endpoint is to compare the efficacy of two ATP therapies for FVT episodes. The study will enroll a minimum of 900 patients within 2 years, followed-up for 12 months. The investigation is expected to be completed in 2007. Conclusions: The ADVANCE-D trial is the first large randomized clinical investigation aimed to evaluate optimal programming and efficacy of ATP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |